GlassScriptPhysician profile
John A Goldman
NPI 1922170836
$33,287.25
in general payments reported to CMS, 2019-2025
29 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,628 · 2021: $7,003 · 2022: $2,070 · 2023: $589 · 2024: $1,380 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.21 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22,085.74 | 2019-2025 | Evenity, Krystexxa, Tavneos |
| Janssen Biotech, INC. | $2,612.69 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $2,144.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $952.58 | 2019-2025 | |
| Pfizer INC. | $873.78 | 2019-2025 | |
| Ucb, INC. | $575.08 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $502.06 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $411.98 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $398.00 | 2019-2022 | |
| Horizon Therapeutics Plc | $337.22 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $306.69 | 2022-2023 | Lupkynis |
| Ani Pharmaceuticals, INC. | $259.79 | 2024-2025 | Purified Cortrophin Gel, Sovuna, Oxistat |
| Sobi, INC | $244.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.55 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $231.35 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $184.84 | 2020-2025 | Acthar |
| Radius Health, INC. | $171.39 | 2019 | |
| Glaxosmithkline, LLC. | $169.67 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $157.01 | 2019-2021 | |
| Argenx US, INC. | $137.26 | 2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $94.98 | 2019-2021 | |
| Celgene Corporation | $85.24 | 2019 | |
| Invivyd INC | $21.58 | 2025 | Pemgarda |
| Genzyme Corporation | $19.61 | 2019 | |
| Merck Sharp & Dohme LLC | $18.59 | 2019 | |
| Pacira Therapeutics, INC. | $15.62 | 2019 | |
| Shire North American Group INC | $14.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.84 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $8.23 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.